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Abstract
Background: Beyond survival of nowadays >80%, modern childhood cancer treatment strives to preserve long-term health
and quality of life. However, the majority of today’s survivors suffer from short- and long-term adverse effects such as
cardiovascular and pulmonary diseases, obesity, osteoporosis, fatigue, depression, and reduced physical fitness and quality of
life. Regular exercise can play a major role to mitigate or prevent such late-effects. Despite this, there are no data on the
effects of regular exercise in childhood cancer survivors from randomized controlled trials (RCTs). Primary outcome of the
current RCT is therefore the effect of a 12-months exercise program on a composite cardiovascular disease risk score in
childhood cancer survivors. Secondary outcomes are single cardiovascular disease risk factors, glycaemic control, bone health,
body composition, physical fitness, physical activity, quality of life, mental health, fatigue and adverse events (safety).
Methods: A total of 150 childhood cancer survivors aged ≥16 years and diagnosed ≥5 years prior to the study are recruited
from Swiss paediatric oncology clinics. Following the baseline assessments patients are randomized 1:1 into an intervention
and control group. Thereafter, they are seen at month 3, 6 and 12 for follow-up assessments. The intervention group is
asked to add ≥2.5 h of intense physical activity/week, including 30 min of strength building and 2 h of aerobic exercises. In
addition, they are told to reduce screen time by 25%. Regular consulting by physiotherapists, individual web-based activity
diaries, and pedometer devices are used as motivational tools for the intervention group. The control group is asked to keep
their physical activity levels constant.
Discussion: The results of this study will show whether a partially supervised exercise intervention can improve
cardiovascular disease risk factors, bone health, body composition, physical activity and fitness, fatigue, mental health and
quality of life in childhood cancer survivors. If the program will be effective, all relevant information of the SURfit physical
activity intervention will be made available to interested clinics that treat and follow-up childhood cancer patients to
promote exercise in their patients.
Trial registration: Prospectively registered in clinicaltrials.gov [NCT02730767], registration date: 10.12.2015.
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Background
Thanks to improvements in diagnosis, treatment and sup-
portive care of childhood cancer patients, 5-year survival
rates have increased drastically since the 1960s and
reached 81% in the last decade in Europe [1, 2], including
Switzerland [3]. However, childhood cancer survivors
(CCS) are at risk to develop a series of physical or psycho-
logical late-effects, either directly as a result of the tumour
and the aggressive treatments received, or secondary due
to an unfavourable lifestyle [4–6]. The authors of a recent
study estimated that 96% of CCS suffer from any chronic
health condition and 81% from a serious or life-
threatening chronic disease by the age of 45 years [7].
These late-effects shift the focus of modern childhood
cancer treatment and research from pure survival to long-
term functionality, health and quality of life [8].
Based on evidence from the general population or adult
cancer survivors, we can hypothesise that regular physical ac-
tivity has the potential to decrease the survivors’ risk for late-
effects, such as cardiovascular diseases (CVD) [9–11], stroke
[11, 12], second cancers [11, 13], obesity [11, 14], dyslipidae-
mia [15, 16], insulin resistance and diabetes mellitus [11, 17],
osteoporosis [18–21], depression [22, 23], and cognitive de-
cline [24, 25]. Despite these encouraging findings on benefits
of exercise in various populations, specific studies on physical
activity interventions in adult or adolescent survivors of
childhood cancer aiming to reduce late-effects and increase
physical activity are scarce. Small controlled exercise inter-
ventions over 2–4 months have shown beneficial effects on
fatigue [26], metabolic risk factors and fitness [27], but to
date no randomized controlled studies have been published.
Furthermore, traditional physical activity interventions
in any field usually focus on specific types of exercises
(such as strength training, tai chi, etc.) and participants
are invited several times per week to join exercise sessions
[28]. The problem of such a supervised and standardized
approach is that the increase in physical activity is often
not maintained by individuals after the intervention has
ended and does therefore not lead to a sustained change
in their behaviour [28, 29]. Our study is novel in applying
an individual and motivational feedback-based approach
with a personalized exercise counselling and program em-
bedded in each participant’s daily life. Such an interven-
tion may have a higher potential to result in a lasting
behaviour change towards an active lifestyle and therefore
ameliorate physical and psychological late-effects.
Methods/design
This study protocol is written in accordance with the SPIRIT
guidelines [30] (see the SPIRIT Checklist in Additional file 1).
Study objectives
The primary objective of the proposed study is to evaluate
the effect of a partially supervised and personalized physical
activity program on the cardiovascular disease (CVD) risk
of adolescent and adult survivors of childhood cancer in a
randomized controlled trial. Secondary objectives are to
assess the effect of the physical activity program on single
CVD risk factors, glycaemic control, bone health, body
composition, physical fitness, physical activity, quality of
life, mental health, fatigue and adverse events (safety).
Primary outcome
The primary outcome of the randomized controlled trial
(RCT) is defined as the change in a composite CVD risk
score [31, 32] from baseline to 12 months in the participants
of the intervention group compared to the participants of
the control group. The composite score is based on the as-
sumption that a physical activity intervention shall have
overall beneficial effects on the cardio-metabolic risk, affect-
ing most if not all components of the metabolic syndrome.
We chose a composite CVD risk score because the preva-
lence of single components of the metabolic syndrome is
low in adolescents and young adults. A longitudinal study
showed that a clustered score in adolescents predicted
metabolic syndrome in adulthood [33] and was sensitive to
change by a physical activity intervention in youth [34]. The
composite CVD risk score will be calculated by averaging
the z-scores based on gender- and age-specific external
references of all components of the metabolic syndrome,
including waist circumference, blood pressure, homeostatic
model assessment insulin resistance [HOMA-IR], inverted
high density lipoprotein cholesterol, triglycerides and
cardiorespiratory fitness [32, 34–39].
Secondary outcomes
Secondary outcomes are differences in change between the
intervention and control group from baseline to 6 months
for the composite cardiovascular disease risk score, and
from baseline to 6 and 12 months for the single CVD risk
factors, glycaemic control, bone health, body composition,
physical fitness, physical activity, quality of life, mental
health, fatigue and adverse events (safety). Additional file 2:
Table S1 lists all assessed outcome variables.
Study design
This study is a single-centre RCT including childhood can-
cer survivors from various paediatric oncology clinics of
Switzerland. Control and intervention arms run parallel
(Fig. 1). Assessments are performed at baseline (T0) and
after three (T3), six (T6), and 12 (T12) months. The assess-
ments at T0, T6 and T12 comprise of two visits (a and b,
respectively) in the study centre, 14 days apart, and T3 of
one visit. Randomization is performed after the first visit of
T0 (T0a) (Additional file 2: Table S1, Fig. 1). A motivational
interview for the intervention group is performed at the
second visit of T0 (T0b). After the intervention period, con-
trols are offered a similar personalized exercise programme
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without long-term coaching (see paragraph on physical
activity intervention). Eligible participants are contacted,
informed and, if consenting, enrolled into the study (see
paragraph on recruitment) until we reach the pre-defined
number of participants.
Ethics
The study was approved by the Swiss Ethics Committee on
research involving humans (Ethikkommision Nordwest- und
Zentralschweiz [EKNZ]). Informed Consent as documented
by signature is obtained from each survivor prior to partici-
pation in the study. Data protection is assured by pseudony-
mization and can only be decrypted by study personnel
involved in this research.
Study population / inclusion criteria
Eligible participants are identified by the Swiss Childhood
Cancer Registry (SCCR) [40, 41]. SURfit includes CCS aged
<16 years at diagnosis, diagnosed with a cancer classifiable
according to the International Classification of Childhood
Cancer (ICCC-3) [42] or Langerhans Cell Histiocytosis, who
were diagnosed and treated at a clinic of the Swiss Paediatric
Oncology Group (SPOG), survived ≥5 years since primary
cancer diagnosis or any subsequent cancer event (relapse or
2nd tumour), and, are aged ≥16 years at baseline (T0a) of
the study. Participants have to agree that they will commit to
the conditions of their study group allocation prior to the
allocation and independent of the allocation.
The presence of any of the following criteria, assessed at
baseline (T0a), leads to exclusion of the participant:
participation in another clinical trial, inability to exercise or
exercise potentially harmful, pregnant or breast feeding,
cardiac arrhythmias under exercise, diagnosis of diabetes
<3 months previously, detection or presence of a clinical
condition that needs immediate treatment, planned surgeries
within the subsequent 12 months that interfere with physical
exercising, major musculoskeletal injuries/fractures <2months
previously, change in medication that interfere with the pa-
rameters of the CVD risk score < 1 month previously, >4 h of
reported vigorous physical activities per week, or, inability to
follow the procedures and understand the intervention and
assessments of the study, e.g. due to cognitive impairment,
language problems, or psychological disorders.
Recruitment
Eligible patients are contacted with an information letter
from their former treating hospital including a short study
information brochure. Interested survivors then receive the
detailed patient information of the study and the informed
consent. Survivors decide upon this information whether
or not they want to participate in the study. A study hotline
or the responsible investigator can be contacted to clarify
remaining questions about the study. All survivors who do
not react to the study invitation are followed-up by a phone
call and asked about their interest in the study. Survivors
who decide to participate are invited for the baseline assess-
ment where final decision upon eligibility is made and the
informed consent is obtained.
We record the reasons for non-participation of each
contacted survivor who does not want to participate. In
addition, basic information on demographics and clinical
factors are available from the SCCR on non-participants.
This will allow us to get information on the representa-
tiveness of the participants in the study.
Fig. 1 SURfit study design. Shows the general design and procedure of the SURfit study. All visits of T0, T3, T6 and T12 are at the University Children’s
Hospital Basel (UKBB) including a visit at the Bone Research Unit of the University Hospital Basel (USB) to perform the DXA and pQCT scans (T0a and
T12a). After one year of trial, participants of the control intervention who wish to, can receive the same personalized exercise counselling with
motivational tools but no personal follow-up coaching. Participants of the intervention group will hopefully continue their training without supervision
of the study team but still having access to the motivational tools of the study. Abbreviations: DXA, dual x-ray absorptiometry; mt, months; oGTT, oral
glucose tolerance test; pQCT, peripheral quantitative computed tomography; SCCR, Swiss Childhood Cancer Registry; T0a, initial baseline visit; T0b,
second visit for baseline assessments; T3, assessment after 3 months; T6a and T6b, first and second visit of assessments after 6 months; T12a and T12b,
first and second visit of assessments after 12 months
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Randomization
To ensure high quality randomization and even distribution
of important prognostic factors among the intervention and
the control group, a web-based minimization randomization
approach (Randomizer: Institute for Medical Informatics,
Statistics and Documentation, Medical University of Graz,
Austria; available at www.randomizer.at) is used for the 1:1
allocation of participants into the two study arms [43]. We
include gender and four categories according to the initial
cancer diagnosis (leukaemia and lymphoma; CNS tumours;
bone tumours and soft tissue sarcomas; other diagnoses) as
grouping variables in the randomization. An external
collaborator who is independent of the patient recruitment
and enrolment process runs the randomization and
treatment allocation (Additional file 2: Table S1).
Measurements
Additional file 2: Table S1 gives an overview of the measure-
ments and procedures at each time point of the study;
Additional file 3 summarizes the measurements and respect-
ive methods used. Standard operating procedures (SOP)
were developed for each measurement prior to the beginning
of the study to reach a high level of standardisation and reli-
ability. All assessors were extensively trained for the specific
methods including pilot assessments prior to the study.
Regular internal inspections of the assessments are carried
out to maintain high methodological quality.
Study data are collected and managed using REDCap
electronic data capture tools hosted at the Clinical Trials
Unit, University of Bern [44]. All self-reported question-
naires are filled in by the participants directly in the RED-
Cap database with a personal login during the study visits.
All data entries are double-checked for consistency, errors
and completeness by a data monitor. The data monitor, a
member of the study team but independent of all the
assessments, notifies any problem encountered back to
the assessor using the specified feature in REDCap.
Bloods
Fasted blood samples are taken in the morning after an
overnight fast of at least 8 h. Glucose and glycated haemo-
globin (HbA1c) are analysed within a few hours after sam-
pling at the laboratory of the University Hospital of Basel.
The other parameters assessed in the blood serum and
plasma are centrifuged, divided into 1.0 ml aliquots and
stored at −70 °C to be analysed at a later time point when
a test kit can be completed at a the certified laboratory of
the Endonet and Bone Research Unit, Basel.
Cardiovascular disease risk
Blood pressure
Systolic and diastolic blood pressure is measured in sitting
position on the left upper arm after at least 5 min rest using
an automated oscillography (DINAMAP® ProCare [GE
Medical Systems, Tampa, Florida, USA]). Based on the rec-
ommendations of the American Heart Association, the
mean of two readings with a one-minute interval between
them are recorded [45]. If the difference between the two
readings is >5 mmHg, another two readings are taken [45].
Anthropometry
Standing height and weight are taken by standard proce-
dures, barefoot and in underwear. Height is determined to
the nearest 0.5 cm, weight is determined to the nearest
0.1 kg. Waist circumference is measured with a medical
measuring tape to the nearest 0.5 cm. It is measured at the
narrowest part of the torso (the middle between lower rib
arch and spina iliaca) in relaxed, standing position at the
end of expiration [46, 47]. Skinfold (SF) thickness is
measured in triplicate to the nearest 0.2 mm with a
Harpenden calliper (Harpenden Skinfold Calliper [Baty
International, West Sussex, United Kingdom]) on the right
body site at sites over triceps, biceps, subscapular and
suprailiacal based on standard procedures [48, 49]. The
sum of the four SF (each averages of the three readings) is
taken to calculate absolute [kg] and relative [%] body fat by
a formula validated against underwater weighing [49]. With
this formula, body fat can be estimated with 3–5% error
[49]. Lean body mass is derived from total body mass and
body fat. Furthermore, percent fat mass, absolute fat mass
and lean body mass (total body and regional) are estimated
by whole body dual x-ray absorptiometry (DXA) using a
Hologic Discovery densitometer (Hologic, Bedford MA,
USA) [50, 51]. Body composition estimation from DXA
scan shows good precision with a 2–3% coefficient of
variation (CV) [52]. Muscle cross-sectional area (CSA)
[cm2 and z-scores] at proximal tibia and radius is assessed
using peripheral Quantitative Computed Tomography
(pQCT, Stratec XCT 2000 scanner; Stratec Medical
Pforzheim, Germany). Muscle CSA is obtained by subtract-
ing fat CSA and bone CSAs from the CSA of the total limb.
Precision error for muscle CSA determination of the calf
by pQCT was found to be between 0.5%–4.1% [53–55].
Glycaemic control
Serum levels for insulin and C-peptide are determined by
chemiluminescent enzyme immunoassays (ECLIA). The re-
producibility based on the Elecsys 2010 Analyzer is 2.5–
2.8% for insulin and 1.8–5.0% for C-peptide, respectively.
Glucose is measured by the hexokinase method (Modular),
consisting of a control unit, a core unit and an analytic ISE
unit (E-module). Insulin resistance (IR) is estimated by cal-
culating homeostasis model assessment (HOMA-IR) index
(fasting serum insulin [μU/ml] × fasting plasma glucose
[mmol/l)/22.5]) [56]. HbA1c is measured by a high effi-
ciency fluid chromatography HPLC (VG8). In addition, 2 h
75 g oral glucose tolerance test (oGTT) after an overnight
(≥8 h) fast is done to assess insulin resistance [57–59].
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Blood lipids
Total cholesterol, high-density lipoprotein (HDL) choles-
terol, low-density lipoprotein (LDL) cholesterol and triglyc-
erides are measured by standard method on an auto-
analyser (COBAS Integra 800; Roche Diagnostics, Basel,
Switzerland). Intra-assay and inter-assay CVs are between
1.6–2.2% for total cholesterol, 2.4–3.6% for HDL, 0.7–2.1%
for LDL, and 1.1–3.7% for triglycerides, respectively.
Bone health
Bone mineral content and density
Bone mineral content (BMC, g), bone area (BA, cm2) and
areal bone mineral density (aBMD, g/cm2) are measured
at the lumbar spine, femoral neck and hip by DXA using a
Hologic Discovery densitometer (Hologic, Bedford MA,
USA) according to existing guidelines [60]. For aBMD
evaluation at the lumbar spine, mean aBMD data of verte-
bral bodies L1 to L4 are reported unless vertebral bodies
showing artefacts need to be excluded. A single densitom-
eter is used throughout the study. In a previous study, the
CV of individual measurements was 1.1% for the spine,
1.4% for the femoral neck, 1.9% for the trochanteric re-
gion, and 1.1% for the total hip [61]. The total radiation
exposure of a DXA scan is 3–6 μSv.
Trabecular bone score (TBS)
Measurement is performed using spine DXA files with the
TBS iNsight Software (version 1.8; Med-Imaps, Pessac).
The software uses the antero-posterior spine raw image(s)
from the densitometer, including the BMD region of inter-
est and edge detection so that the TBS calculation is per-
formed over exactly the same region of interest as the
aBMD measurement. It assesses the heterogeneity of the
areal density, with a higher heterogeneity implying poorer
trabecular connectivity. Short-term reproducibility (CV)
for TBS is reported to be 2.1% and 1.7% for spine aBMD
in 92 individuals with repeat spine DXA scans performed
within 28 days [62, 63].
Vertebral fracture assessment (VFA)
Is an established, low radiation method for detection of
prevalent vertebral fractures using DXA [64]. Lateral spine
scans are performed simultaneously with aBMD measure-
ments using the Hologic Discovery densitometer. Spine
fractures are classified using the standard semi quantitative
scoring system of Genant and colleagues [65]. This scoring
system differentiates three fracture grades based on the
height reduction of the affected vertebral body (grade 1:
20–25%; grade 2: 25–40%, grade 3:>40%) [65].
Bone architecture & strength
Volumetric bone density (vBMD), bone mass, and bone
geometry is measured using pQCT (Stratec XCT 2000
scanner; Stratec Medical Pforzheim, Germany) at the distal
epiphysis and diaphysis of the non-dominant lower leg and
lower arm. We will assess bone total CSA in mm2 at the
epiphyseal and diaphyseal sites, cortical CSA (excluding the
medullary CSA) in mm2 at the diaphyseal sites, total and
trabecular vBMD in mg/cm3 at the epiphyseal sites, and
cortical BMD in mg/cm3 at the diaphyseal sites [66, 67].
Absolute values are transformed in z-scores based on refer-
ence values [68, 69].
Quantitative computed tomography measures attenuation
of x-rays projected through the limb at one-degree steps
covering 180 degrees, resulting in an image of the cross-
section of the limb. The slice thickness of 2 mm allows a
three-dimensional (volumetric) assessment of bone density.
X-ray attenuation is linearly transformed into hydroxyapatite
(HA) densities. Unlike some other pQCT scanners, the
Stratec XCT 2000 is calibrated with respect to water which
is set at 60 mg HA, so that fat results in 0 mg HA [70]. HA
equivalent densities are automatically calculated from the
attenuation coefficients by employing the manufacturer’s
phantom which itself is calibrated with respect to the
European Forearm Phantom (EFP; QRM, Erlangen,
Germany) [70]. The effective radiation dose is 0.2 μSv per
scan and per scout view as indicated by the manufacturer.
Radius bone length is set equal to ulnar length, which is
measured to the nearest 5 mm with a measuring tape by
palpation of the olecranon and the ulnar styloid. Tibia
length is measured from the medial knee joint cleft to the
end of the medial malleolus. A scout view of the distal end
of tibia and radius is performed and the automated detec-
tion algorithm provided by the manufacturer is used to
place the reference line at the distal bone end. Two scans
are performed for each of radius and tibia: one at 4% of
total bone length measured from the reference line of the
scout view in the distal epiphysis, and one at 66% of total
bone length in the proximal part of the diaphysis. A
reproducibility study based on 9 subjects with 4 repeated
measurements defined the smallest detectable differences
(1.96 × Standard Deviation [SD]) to be 4.74 and 3.92 mg/
cm3 for trabecular vBMD at the radius and tibia, respect-
ively, and 11.68 and 5.39 mg/cm3 for total vBMD at the
radius and tibia, respectively [71].
Bone metabolism and hormones
Biomarkers of bone metabolism provide a quantitative
measure of the relationship between bone deposition and
resorption. Measuring the balance between deposition and
resorption in relation is the basis of explaining change in
BMD over time and can be taken as determinant of BMD
change. The following biochemical markers of bone turn-
over are assessed: a) bone formation markers: bone-specific
alkaline phosphatase (BAP), osteocalcin (OC), N-terminal
propeptide of type I procollagen (PINP); b) bone resorption
markers: C-terminal telopeptide of type I collagen (CTX).
Serum BAP (IDS-iSYS Ostase BAP) as well as 25-hydroxy-
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vitamin D3 (IDS-iSYS 25-Hydroxy Vitamin D) will be de-
termined using an enzyme-immunoassay (EIA) on the IDS-
iSYS (Immunodiagnostic Systems, Frankfurt/Germany).
The intra- and inter-assay variations are <9% for BAP [72,
73], and 3.6% and 16.9% for 25-hydroxy-vitamin D3 [74,
75], respectively. The parameters beta-CrossLaps (CTX),
N-MID-Osteocalcin, PINP and intact parathyroid hormone
(iPTH) are measured in serum with ECLIA on the auto-
mated analyser Elecsys 2010 (Roche Diagnostics, Rotkreuz,
Switzerland) [76, 77]. The intra- and inter-assay variations
are 2.4–7.2% for CTX, 1.1–5.9% for OC, 1.7–4.0% for PINP,
and 1.7–5.5% for iPTH, respectively [61]. Uncarboxylated
OC (ucOC) is measured after previous incubation of serum
samples with hydroxyapatite (5 mg/ml) to separate out
carboxylated OC (cOC) from the ucOC as previously
described [78]. The ucOC in the supernatant is measured
using the same assay as for total osteocalcin and will be re-
ported as a concentration and as a fraction of the total [79].
Further hormone analyses including thyroid-stimulating
hormone (TSH), free thyroxine (fT4), gonadotropins
(luteinizing hormone [LH], follicle-stimulating hormone
[FSH]), estradiol (E2), total testosterone (TT) and cortisol
will be carried out using ECLIA on the automated analyser
COBAS e411 (Roche Diagnostics, Rotkreuz, Switzerland).
The intra- and inter-assay variations are 1.5–8.7% for TSH,
1.8–7.6% for fT4, 0.8–5.2% for LH, 1.8–5.3% for FSH, 2.4–
11.9% for E2, 1.2–8.4% for TT, and 1.1–1.6% for cortisol,
respectively [80].
Insulin like growth factor 1 (IGF-1) and insulin like growth
factor binding protein 3 (IGF-BP3) are determined using
ECLIA on the IDS-iSYS (Immunodiagnostic Systems, Frank-
furt/Germany). The intra- and inter-assay variations are 6.0%
and 9.8% for IGF-1, and 7.9% and 15.5% for IGF-BP3, re-
spectively [81]. All assays are performed in duplicate by using
the same biomarker kit, and the mean value will be recorded.
Nutrition
To correctly interpret bone health of the subjects, the
relevant parameters like calcium intake [mg/day], protein
intake [g/day] and vitamin D (supplement intake, sun ex-
posure and nutrition) are also assessed with standardized
and validated self-reported questionnaires [82, 83].
Physical fitness
Aerobic fitness
The participants complete a continuous incremental cycling
test to volitional exhaustion following the step protocol pro-
posed by Godfrey and colleagues [84] in accordance to the
international guidelines for exercise testing [85, 86]. Work
rate is increased every minute by 20 W with an initial load of
20 W. At each visit, a 12-lead electrocardiogram (ECG, Schil-
ler CS-200, Schiller AG, Baar, Switzerland) at rest is per-
formed to rule out relevant arrhythmias and other
pathologies that may pose a risk to the patient during the
cycling test and/or intervention. All participants are tested
using a calibrated cycle ergometer (Ergospirometrie-System
CS-200 and SCHILLER ERG 911S Plus cycle ergometer
[SCHILLER AG], Baar, Switzerland) and metabolic cart (LF8
PowerCube®-Ergo Gas-Analysator [Ganshorn Medizin Elec-
tronic], Niederlauer, Germany). The metabolic cart is cali-
brated before each exercise test with two gases of known
concentrations. Peak oxygen uptake (VO2peak) is deter-
mined by the highest VO2 averaged over 30s during the test.
Peak performance (Wpeak) is defined as the power main-
tained over the final 1-min stage of the test plus 5 W for
each fulfilled 15 s bout of the non-finished stage. Maximal
aerobic power and VO2peak will be expressed in percent of
predicted [87]. Electrocardiography using chest leads and
oxygen saturation measured at the finger (Masimo SET-
Monitor Radical-7, [Masimo Corporation], Irvine, USA) are
used to monitor the participant throughout the test for safety
reasons and to determine maximal heart rate and desatur-
ation under exercise. The test is terminated according to
existing guidelines [86]. Blood pressure and Borg Rating of
Perceived Exertion (RPE) are assessed at the end of each
stage [88, 89]. In addition, heart rate, blood pressure and
Borg RPE are assessed 1, 2, and 3 min post exercise to assess
recovery as a marker of physical fitness [90].
Muscular strength
To assess muscular strength of the lower body, the 1-min
sit-to-stand (STS) test is performed [91, 92]. The participants
perform one test trial at least 20 min before the final test.
The number of repetitions of standing up and sitting down
from a chair in the final test is recorded. In addition, Borg
RPE is assessed at the end of the test [88, 89]. The test is
performed on a height adjustable chair to ensure a 90° knee
angle. The 1-min STS test showed high reliability and good
criterion related validity with other exercise capacity tests
such as the 6-min walk test or stair climbing [93–96]. Exist-
ing population-based reference values from Switzerland will
help to identify subjects with decreased lower body muscular
strength and endurance [91].
Upper body strength is assessed through a handgrip
strength test using the JAMAR Hydraulic Hand Dynamom-
eter (Lafayette Instrument®, Lafayette, USA). The JAMAR
dynamometer was validated in several studies and is
regarded as the gold standard in measuring handgrip
strength [97]. The dynamometer assesses force in kg (0–
90 kg) to the nearest 2 kg. Hand grip strength is measured
according to the American Society of Hand Therapists
(ASHT) recommendations in a sitting position on a height
adjustable chair with the dynamometer resting on a table in
front of the subject [98]. Each hand is measured 3 times,
with alternating sides, starting with the right hand and one
minute breaks between measurements. A 1-min break is
described as sufficient in the literature in order to yield
consistent values [99].
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Physical activity
Pedometer
Participants wear a pedometer (Fitbug Air®, Fitbug,
London, United Kingdom) between the two visits of T0,
T6 and T12, to count number of daily steps (divided into
overall steps and aerobic steps) [100]. The steps per day of
the preceding 14 days are stored in the device and entered
into the REDCap database when the participant returns
the device at the second visit.
In addition, participants of the intervention group will
wear a pedometer and record their daily steps through-
out the entire study period (see paragraph on physical
activity intervention).
Accelerometer
Physical activity (PA) is assessed by accelerometer
(ActiGraph, Pensacola, Florida, USA) which will be worn
on the right hip during at least 7 days between the two
visits of T0, T6 and T12. The device measures accelerations
of ±6 G. The sample rate of the accelerometer will be set to
measure raw signals at 100 Hz. These are then translated
into either metabolic energy equivalents of no, light, mod-
erate and vigorous physical activities to estimate the effect
on the metabolic outcomes or in cumulative impacts per
day for the bone outcomes. Data are included if at least four
full days (including at least one weekend day) with a mini-
mum of 10 h are measured [101]. Participants are asked to
wear the accelerometer also at night to capture sleeping
time. Validity of accelerometer is good with correlation co-
efficients of 0.65 between accelerometer assessed metabolic
energy equivalents and indirect calorimetry [102], and 0.74
between accelerometer impact loading and ground reaction
forces by force plates [103]. For metabolic outcomes, over-
all PA will be expressed as total PA (total counts), average
PA in counts/min, as well as time (min/d) sedentary and in
light, moderate and vigorous PAs according to proposed,
previously published cut-off levels [101, 102, 104]. For bone
outcomes, impact loading will be expressed as cumulative
impacts per day (n/day) >2, 3, 4, 5 and 6 G, respectively.
Less than 100 impact loadings >3.9 G per day were shown
to be effective to increase bone mineral density in premen-
opausal women with higher effects in those with low base-
line values [105]. Such a level is reached with jogging, fast
running and jumping activities.
Questionnaire
The Seven-Day Physical Activity Recall questionnaire
(PAR), the Exercise Motivations Inventory (EMI-2) and a
self-constructed questionnaire including items of the Lipid
Research Clinics questionnaire (LRC) are used to assess the
time individuals engage in physical activity, their reasons
for exercising, and type and time of sports. The PAR as-
sesses the time an individual engaged in moderate, hard,
very hard activities and sleep during the 7 days prior to the
assessment [106]. The PAR was validated in several studies
against objective measures of physical activity and showed
satisfying psychometric properties in different populations
such as children and adults [106–109]. The EMI-2 is a vali-
dated scale to measure an individual’s reason for exercising.
It comprises of 44 items reflecting 12 dimensions including
stress management, weight management, recreation, social
recognition, enjoyment, appearance, personal development,
affiliation, ill-health avoidance, competition, fitness and
health pressures [110, 111]. The self-constructed question-
naire includes items on type and time of current sports and
questions from the validated LRC [112].
Quality of life and mental health
Health related quality of life
Is assessed using the Short Form-36 (SF-36) [113, 114].
This instrument is validated and has been successfully used
in samples of long-term CCS [115–119]. It consists of 36
questions that can be summarized into eight scales: physical
functioning, role limitation due to physical health (role
limitation physical), bodily pain, general health perception,
energy & vitality, social functioning, role limitation due to
emotional problems (role limitation emotional), and mental
health. The eight scales can be further aggregated into a
Physical Component Summary (PCS) and a Mental Com-
ponent Summary (MCS) [114]. We will convert raw scores
into T-scores (mean = 50, SD = 10, range 0–100) according
to age- and sex-stratified norm data from a public use-file
of the German Federal Survey (N = 6964) because no Swiss
data of the SF-36 are available [113].
Fatigue and actual well-being
Is assessed with a Visual Analogue Scale (VAS) and the
Checklist Individual Strength (CIS). A VAS for fatigue and
well-being is designed to measure these characteristics,
which are believed to range across a continuum of values
and cannot easily be measured directly. Operationally, the
VAS is a horizontal line, 100 mm in length, anchored by
two word descriptors at each end. In our study, the
descriptors will range from ‘not tired at all’ to ‘completely
exhausted’ for fatigue and from ‘feeling absolutely
miserable’ to ‘perfect well-being’ for well-being. The CIS is
a validated 20-item questionnaire, that is designed to meas-
ure four aspects of fatigue that may have been experienced
during the previous 2 weeks, i.e. severity of fatigue (8
items), concentration (5 items), motivation (4 items) and
physical activity (3 items) [26, 120, 121]. Each item is scored
on a 7-point Likert scale. The total score is the sum of the
scores 1–7 in the 20 items (range 20–140). Norm scores
are available for different patient groups and healthy people.
The CIS has also been successfully used in long-term survi-
vors of childhood cancer [26]. The CIS showed to have
good internal consistency and validity across studies and
could successfully discriminate between non-fatigued and
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fatigued groups and cut-off points for clinical levels of
fatigue have been developed [26, 122, 123].
Mental health
Psychological distress will be assessed using the Brief
Symptom Inventory (BSI) [124]. The BSI is a widely used
and well-validated instrument to screen the following nine
domains of distress: somatization, obsessive-compulsive
tendencies, interpersonal sensitivity, depression, anxiety,
aggression, phobic anxiety, paranoid ideation, and psych-
otic tendencies. Responses to all 53 items can be further
summarized in the Global Severity Index (GSI). For each
item, participants express how much they agree with a
statement describing the previous 7 days on a 5-point
Likert-scale ranging from 1 (not at all) to 5 (very much).
Scores from all scales will be transformed to T-scores
(mean = 50, SD = 10, range 0–100) according to the Ger-
man norm population [125]. A T-score of ≥63 on any scale
corresponds to the 90th percentile of the norm population
and indicates a risk for being at significant psychological
distress in this area (case rule) [125].
Personal history and clinical examination
A thorough personal history, study of the medical record
and clinical examination is performed in each participant,
with special emphasis on the cancer history, signs and
symptoms of cardio-metabolic, pulmonary or neurological
diseases, health behaviour, medical doctor visits, hospitaliza-
tions, and medications [126–128]. Symptoms, medical doc-
tor visits, hospitalizations and medications are updated after
6 and 12 months. Physical examination of the lungs, heart,
abdomen, joints, extremities, ears, mouth, lymph nodes and
a detailed neurological status are performed at baseline and
after 6 and 12 months. Vital parameters including heart rate
and blood pressure are taken at every visit. Tanner stadium
is assessed once at baseline and only repeated after 6 and
12 months if the participant is not fully mature at baseline
[129]. Socio-demographic characteristics are assessed by
questionnaire at baseline, health behaviours at baseline and
after 12 months, using standardized questions from the
Swiss Health Survey and the Swiss Census [126–128].
Adverse events and exercise related complications
Every adverse event including exercise related complica-
tions [130] whether or not causally related with the exercise
training will be monitored based on standardized proce-
dures and followed until resolved [131]. Each adverse event
is recorded in the REDCap database and classified based on
The Common Terminology Criteria for Adverse Events
(CTCAE) [131]. Serious adverse events are reported to the
sponsor and the responsible independent ethics committee.
An independent safety auditor of the University Children’s
Hospital Basel (UKBB) is monitoring patients’ safety
throughout the study period.
Participants who show an elevated blood pressure or a
pathological oral glucose tolerance test at baseline or
during a study visits, can enter/stay in the study, but are
referred to the family physician or a specialist to get the
appropriate treatment. In case of diabetes, the partici-
pant will enter the study once a stable condition is
reached but earliest after 3 months.
Participants at risk for cardiac late-effects due to cardio-
toxic childhood cancer therapy (anthracyclines and/or chest
radiation) can enter the study normally, but are recom-
mended to get a cardiac assessment with an adult
cardiologist according to recent recommendations [132].
Physical activity intervention (intervention group)
Survivors in the intervention group are asked to add at
least 2.5 h of intense physical activities per week. These
should include 30 min of strength building exercises and
2 h of aerobic exercises per week. Exercise bouts lasting
20 min or longer are counted towards the total weekly
training time. This “dose” of physical activity is based on
the international recommendations of healthy physical ac-
tivities from the Centre of Disease Control and Prevention
(CDC; www.cdc.gov) [133].
Based on the initial exercise test, general health status and
participant’s preferences and motivation, subjects of the
intervention group receive a counselling at the second visit
of the baseline assessment (T0b; Fig. 1, Additional file 2:
Table S1). A standardized approach is used to assess survi-
vors’ preferences with respect to physical activities, identify
possible barriers and determine the individual motivation to
start specific activities. Based on this assessment, individual-
ized physical activities are defined and implemented into the
participant’s daily life. Survivors of the intervention group are
also motivated to incorporate activities of moderate
intensities into daily life such as walking instead of driving or
climbing stairs instead of taking the escalator. Participants
are also advised to reduce inactive behaviour such as televi-
sion viewing, computer games, etc. with the aim of reducing
25% of their actual media time. The motivational interview is
performed by one of the project physiotherapists who have
been trained prior to the study.
For motivational reasons each survivor of the intervention
group is equipped with a step counter (pedometer, Model
Fitbug Air) and asked to document daily steps. Participants
keep a daily training log using a web-based platform with
individual anonymous logins. Data on 1) strenuous exercise
performed that day (type of exercise, duration), 2) step
counts (overall and aerobic steps), 3) media-related sedentary
time and sleeping hours, and 4) mood and well-being are
entered and graphically displayed to give the participants an
immediate feedback about their progress. The participants
receive a “reminder” message on his or her mobile phone or
via email if no entries are made for three consecutive days. If
there are no entries for a whole week, the survivor is
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contacted by phone by his “personal coach” (physiotherap-
ist). There are also scheduled phone contacts after 1, 2, 4, 5,
8 and 10 months of the intervention to discuss compliance,
motivation, and progress and to re-counsel the survivors on
their training plan. Training logs and physical activity
behaviour are checked and discussed during the clinic visits
(at months 3 and 6), and exercise counselling is repeated.
After the 1-year assessment, participants of the interven-
tion group can keep their step counters and will still have
access to the web-based training log to report and view their
activity data, but no further support is given from the re-
search team. A follow-up after 1–2 years off trial is planned
but this is not subject of the current study protocol.
Control group
The control population of this study is asked to keep its ac-
tivity level constant over the one-year study period. With this
study, we will be able to test the effect of additional physical
activity compared to a “normal” activity level. After the one-
year study period, participants of the control population have
the opportunity to receive the same personalized physical
activity counselling and motivational interview, but without
personal follow-up coaching. They also receive a step
counter and access to the same web-diary, which they can
use to follow their physical activity plan.
Compliance
Compliance of the participants is assessed by different means.
This will allow us to validate whether the aims of the inter-
vention and control arm have been maintained and to make
dose-response analyses for physical activity in this population.
Participants of the intervention group daily report the ped-
ometer steps and sports performed in the web-diary, they
are contacted immediately in case of non-compliance, they
have monthly telephone contacts with the physiotherapists,
and three-to-six-monthly assessment visits with the physi-
cians, physiotherapists and other staff. After the one-year
intervention, a structured interview is performed with the
participants of the intervention group to assess their opinion
on the intervention, their compliance, reasons for compli-
ance or non-compliance and readiness to continue the phys-
ical activity programme. Furthermore, at each study visit (3,
6, and 12 months), the retained steps of the pedometers over
2 weeks prior to the visits are (unknown to the participants)
downloaded and entered into the study database to assess
how accurate participants of the intervention group report
their daily steps in the web-diary.
Participants of the intervention and control group report
their actual activities at each visit (T3, T6, and T12) and we
objectively measure the activity levels at T6 and T12.
Blinding
With our physical activity intervention, it will not be pos-
sible to blind the study participants themselves, the project
physiotherapists, the project physicians and some of the
assessors. But wherever possible all other members of the
project team will be blinded for group allocation of the
participants, i.e. those who perform the DXA measurement,
the physical performance test, the blood analysis, the
quality check of the data in the database and the statistical
analysis.
Sample size
A study by Kriemler and colleagues using the same CVD
risk score showed a reduction in the z-score by 14% after a
1-year physical activity intervention in children and adoles-
cents [34]. Our population is older with a history of cancer,
intensive treatments and long hospitalisations. We there-
fore expect higher CVD risk in this population at baseline
and even greater changes after an intervention. To be con-
servative, this study is powered to detect a difference be-
tween the intervention and control group of 15% (no
change in the control group and 15% change in the inter-
vention group) after the 1-year intervention. For a power of
0.80 and a two-sided type 1 error probability of 0.05, 60
survivors with complete data are required in each study
arm. Assuming that 20% of participants will dropout or
have missing data, 75 survivors have to be recruited in each
arm. From the Swiss Childhood Cancer Registry we identi-
fied 4241 eligible 5-year survivors of whom about 1500
were diagnosed and treated in one of the three Swiss
Paediatric Oncology Group (SPOG) clinics of initial recruit-
ment (Basel, Lucerne, and Zurich) [3]. Therefore, with an
expected participation rate of 20% of the survivors con-
tacted and invited, we will reach a sufficient sample size.
Data analysis
Descriptive statistics will be used for clinical, sociodemo-
graphic and prognostic variables measured at baseline
(stratified by intervention and control group). We will use
frequencies and proportions with 95% confidence intervals
(CI) for categorical variables and mean with ±SD or 95% CI
(or median and range) for continuous variables. Descriptive
analysis of baseline characteristics will be performed as
soon as the baseline assessments are completed for all
participants. This cross-sectional analysis will inform about
the comparability of the treatment groups and the need for
adjustment of between treatment group comparisons.
Furthermore, baseline assessments will provide important
results about characteristics, health behaviours and health
status of long-term CCS in Switzerland. We will also
compare the distribution of baseline sociodemographic
characteristics to the Swiss Childhood Cancer Registry, to
estimate the representativeness of our sample.
The primary analysis will be conducted as intention-to-
treat analysis (ITT) for the primary outcome (change in
composite CVD score from T0 to T12). All participants
will be analysed in the group where they were originally
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allocated and missing data will be imputed by means of
last observation carried forward (LOCF) [134]. LOCF is
an appropriate procedure in this setting because it will
lead to more conservative effect estimates (i.e. towards the
null), because lost to follow-up is more likely to occur in
the intervention group (because of an intensive and time-
consuming programme) which is the group expected to
change (improve). Attempt will be done to follow up all
randomised participants, even if they withdraw from the
allocated treatment. If the parameters of the composite
CVD risk score are skewed, they will be transformed to
reach normal distribution for calculating the z-scores.
The secondary analyses include several steps: First, we
will do the same ITT analysis with appropriate means of
imputation of missing data for all the secondary outcomes.
Second, we will perform sensitivity analysis on the primary
and all secondary outcomes, including, a) complete data
(complete case analysis), i.e. observations with missing in-
formation on relevant variables will be dismissed; b) ana-
lysis of intermediate effects after 3 and 6 months of
intervention; c) dose-response analysis based on the actual
physical activities (min of vigorous physical activities per
week) or physical performance (VO2peak) during the
period of interest, independent of the group allocation;
and, d) per protocol analysis.
Per protocol analysis will include several analyses based
on the actual “treatment” that the participants adhered to
(independent of group allocation), first based on the re-
ported compliance and second based on the assumed
compliance. In the first analysis based on the reported
compliance, the following participants will be analysed as
being in the “intervention group”: participants randomized
into the intervention group who reported in the web-diary
to have reached at least 2/3 of the target physical activity
(addition of 100 min of moderate to vigorous physical ac-
tivities [MVPA]); and, participants who were randomized
to the control group but reported in the physical activity
questionnaires to have increased their physical activity
level by more than 30 min of extra MVPA per week
during the period of interest. The rest of the participants
will be analysed as being a “control”. The second analysis
of reported compliance will include only the participants
sufficiently compliant with the protocol that they were al-
located to. It will include those randomized into the inter-
vention group who completed at least 2/3 of training
volume (e.g. the addition of 100 min per week of vigorous
PA) and compare them to those randomized into the con-
trol group with no more than 30 min of extra vigorous PA
per week than at baseline during the period of interest.
The analysis on the assumed compliance will be done
according to the analyses of the reported compliance but
with participants being defined as compliant if they
reach an increase of ≥5% in VO2peak and/or ≥10% in
the ventilatory anaerobic threshold from baseline [135].
Model selection Depending on the type of endpoint,
mixed linear, logistic, Cox or Poisson regression will be
used. All models will include the variables used in the
adaptive randomization (age and former cancer diagnosis)
and we will test the model assumptions and model fit.
The models might be further adjusted for baseline values
and important prognostic factors such as sex, socio-
economic status, health-behaviours, treatments received,
or former treating hospital if we observe an unequal distri-
bution of important confounders between the treatment
and control group.
The analysis will be done with Stata Statistical Software
version 14 or newer (StataCorp LP, College Station, Texas,
USA) and R Statistics (R Core Team, Vienna, Austria,
www.R-project.org). A p-value <0.05 will be considered as
statistically significant. Primary and secondary analyses
will be performed when the data collection is finished for
all participants.
Publication policy
Because of the large variety of outcomes assessed, we in-
tend to publish the effect of the intervention on the differ-
ent outcomes in more than one paper. We intend to
publish the effect of the intervention on our primary out-
come (CVD risk score) and related single cardiovascular
disease risk factors, glycaemic control and body compos-
ition in a single paper (main paper). This publication will
also include the changes in physical fitness and physical
activity as well as the clinical status and safety endpoints.
Beside this, we intend to publish the effect of the interven-
tion in different papers of the following topics:
- Effect on bone health
- Effect on quality of life, mental health and well being
Results of the baseline assessments only and further in
depth research questions will be published in additional
papers of meaningful topics.
Discussion
It’s estimated that 1 in 800 young adults under the age of
35 years living in developed countries is a survivor of
paediatric cancer [2]. Unfortunately, studies have shown
that the vast majority of these survivors present with
chronic medical conditions such as cardiovascular and
pulmonary diseases, 2nd cancers, overweight, osteopor-
osis, or psychological distress, directly impacting their late
mortality, morbidity and quality of life [4, 7, 117, 136].
Physical activity and exercise have become a cornerstone
in the prevention and treatment of chronic diseases
including cancer, cardiovascular morbidity and mortality,
diabetes, osteoporosis, fatigue or increasing psychological
well-being [11, 16, 137–147] Even in palliative care, physical
activity seems to reduce the burden of cancer- or therapy-
related side effects [148]. Despite these striking evidences,
there is a lack of randomized, controlled exercise trials
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aiming to reduce cancer- and therapy-related sequelae in
paediatric cancer survivors, which may ultimately increase
life expectancy, decrease morbidity and lead to an improve-
ment in quality of life. This is especially important for child-
hood cancer survivors as these patients are young with a
long life in front of them.
Besides contributing to the body of scientific knowledge,
this randomized controlled trial will also use a novel
approach with a personalized and partially supervised
exercise intervention. The intervention is supported by
multiple tools such as web-based feedback, pedometers
and individually tailored counselling. With this approach,
we try to overcome barriers and low compliance that is a
major problem in the sustainability of intervention studies.
Moreover, the measurement of most major cardio-
metabolic risk factors and bone health and the inclusion
of patient important outcomes like quality of life and psy-
chological distress provide a complete picture.
Another new aspect is the precise measurement of
bone architecture including a broad battery of possible
determinants of osteoporosis or decreased bone mass in
CCS. This may shed more light on the single and com-
bined risk factors of increased bone fracture risk or
osteoporosis in this population and on the potential pre-
ventive approaches.
The planned physical activity intervention has the po-
tential to become an important pillar in the support of
the whole CCS population. The project will evaluate
whether a 1-year partially supervised program including
exercise counselling with motivational feedback in CCS
(aged 16 years and above) is able to reduce long-term se-
quelae and/or lifestyle-related diseases including but not
limited to cardiovascular and metabolic risks as well as
bone health, physical fitness, mental health, and quality
of life. If the program shall prove effective, the SURfit
material will become available to interested national and
international clinics that treat and/or follow-up child-
hood cancer patients to promote exercise in their CCS.
Additional files
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents. Contains the SPIRIT
Checklist in its original template. The table lists all the recommended items
that should be addressed in a clinical trial study protocol and indicates the
page numbers where the respective item is described. (DOCX 65 kb)
Additional file 2: Table S1. Schedule of enrolment, interventions and
assessments within SURfit (DOCX 138 kb)
Additional file 3: Measures and methods within SURfit at different time
points. The table in Additional file 3 describes in detail the methods used
for each measurement in SURfit. It is an extension of the (Additional file 2:
Table S1) in the paper. (DOCX 81 kb)
Abbreviations
ASHT: American Society of Hand Therapists; BAP: Bone-specific Alkaline
Phosphatase; BMC: Bone Mineral Content; BMD: Bone Mineral Density;
BSI: Brief Symptom Inventory; CCS: Childhood Cancer Survivor; CDC: Centre
of Disease Control and Prevention; CI: Confidence Interval; CIS: Checklist
Individual Strength; CNS: Central Nervous System; cOC: Carboxylated
Osteocalcin; CSA: Cross-sectional Area; CTCAE: Common Terminology Criteria
for Adverse Events; CTX: C-terminal Telopeptide of Type I Collagen;
CV: Coefficient of Variation; CVD: Cardiovascular Disease; DXA: Dual X-Ray Ab-
sorptiometry; E2: Estradiol; ECG: Electrocardiogram; EFP: European Forearm
Phantom; EIA: Enzyme-Immunoassay; EKNZ: Ehtikkommision Nordwest und
Zentralschweiz; EMI-2: Exercise Motivations Inventory; FSH: Follicle-
stimulating Hormone; fT4: free Thyroxine; GSI: Global Severity Index;
HA: Hydroxyapatite; HbA1c: Glycated Haemoglobin; HDL: High Density
Lipoprotein Cholesterol; HOMA-IR: Homeostasis Model Assessment – Insulin
Resistance; ICCC-3: International Classification of Childhood Cancer – 3rd
Edition; IGF-1: Insulin Like Growth Factor 1; IGF-BP3: Insulin Like Growth
Factor Binding Protein 3; iPTH: Intact Parathyroid Hormone; IR: Insulin
Resistance; ITT: Intention to Treat Analysis; LDL: Low Density Lipoprotein
Cholesterol; LH: Luteinizing Hormone; LOCF: Last Observation Carried
Forward; LRC: Lipid Research Clinics questionnaire; MCS: Mental Component
Summary; OC: Osteocalcin; oGTT: oral Glucose Tolerance Test; PA: Physical
Activity; PAR: Seven-Day Physical Activity Recall Questionnaire; PCS: Physical
Component Summary; PINP: N-terminal Propeptide of Type I Procollagen;
p-QCT: Peripheral Quantitative Computed Tomography; RCT: Randomized
Controlled Trial; RPE: Rating of Perceived Exertion; SD: Standard Deviation;
SF: Skinfold; SF-36: Short Form-36; SOP: Standard Operational Procedure;
SPOG: Swiss Paediatric Oncology Group; STS: 1-min sit-to-stand;
SURfit: Survivor Fitness Study; T0, T3, T6, T12: Time point 0, Time point
4 months, Time point 6 months, Time point 12 months; TBS: Trabecular Bone
Score; TSH: Thyroid-stimulating Hormone; TT: Total Testosterone;
ucOC: Uncarboxylated Osteocalcin; UKBB: University Children’s Hospital Basel;
VAS: Visual Analogue Scale; VFA: Vertebral Fracture Assessment;
VO2peak: Peak Oxygen Uptake; Wpeak: Peak Performance in Watt
Acknowledgements
We thank all the survivors for participating in our study! We thank the study
nurses, assistants, master students and physiotherapists for their great work
within the study!
Funding
This study was supported by the Swiss Cancer League (KLS-3175-02-2013),
“Stiftung für krebskranke Kinder, Regio Basiliensis” (Basel), FORCE – “Fondation
Recherche sur le Cancer de l’Enfant” (Lausanne), “Gedächtnis-Stiftung Susy
Rückert zur Krebsbekämpfung” (Basel), and the foundation Henriette &
Hans-Rudolf Dubach-Bucher. CSR has received funding from the European
Union Seventh Framework Programme (FP7-PEOPLE-2013-COFUND) under
grant agreement n° 609,020 - Scientia Fellows. The funding bodies had no role
in the design of the study, data collection, data analysis, data interpretation, and
in the writing of the manuscript.
Availability of data and materials
The data that will be generated and analysed during the current study is not
publicly available due to the sensitivity of the collected data. The data or
parts of the data are available from the corresponding author upon
reasonable request.
Authors’ contributions
SK, HH, NvdW and CSR have designed the study, participated in the
coordination of the study and drafted the article. SK, CSR, CS, AR, HH, PE, CM,
NvdW and SZ developed the study material, established methods and
questionnaires. CSR and SZ managed the study and developed the project
database. SZ, NvdW, AR, SK, CSR, CS and CM participate in conducting the
study. All authors participated in writing the article and have read and
approved the final version.
Ethics approval and consent to participate
The study was approved by the Swiss Ethics Committees on research
involving humans (Ehtikkommision Nordwest- und Zentralschweiz [EKNZ];
reference number: EKNZ-2015-169). Informed Consent as documented by
signature is obtained from each survivor prior to participation in the study.
Consent for publication
Not applicable (this manuscript does not contain data from any individual person).
Rueegg et al. BMC Cancer  (2017) 17:822 Page 11 of 15
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital and
Institute of Basic Medical Sciences, University of Oslo, Sognsvannsveien 9,
0372 Oslo, Norway. 2Department of Health Sciences and Health Policy,
University of Lucerne, Frohburgstrasse 3, 6002 Lucerne, Switzerland.
3Epidemiology, Biostatistics and Prevention Institute, University of Zürich,
Hirschengraben 84, 8001 Zürich, Switzerland. 4Department of Pediatric
Oncology and Hematology, University Children’s Hospital Basel (UKBB),
University of Basel, Spitalstrasse 33, 4056 Basel, Switzerland. 5Institute of
Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, 3012
Bern, Switzerland. 6Paediatric Endocrinology, Pediatric Endocrinology Centre
Zurich AG (PEZZ), Möhrlistrasse 69, 8006 Zürich, Switzerland. 7Children’s
Hospital, University Hospital Würzburg, Josef-Schneider-Str. 2, 97080
Würzburg, Germany. 8Division of Endocrinology, Diabetes, Metabolism and
Bone Research, University Hospital Basel, Missionsstrasse 24, 4055 Basel,
Switzerland. 9University Clinic of Cardiology, Preventive Cardiology and
Sports Medicine, Inselspital, University Hospital Bern, 3010 Bern, Switzerland.
Received: 9 August 2017 Accepted: 20 November 2017
References
1. Gatta G, Corazziari I, Magnani C, Peris-Bonet R, Roazzi P, Stiller C. Childhood
cancer survival in Europe. Ann Onc. 2003;14(5):119–27.
2. Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P,
Pastore G, Peris-Bonet R, Stiller CA. Survival of European children and young
adults with cancer diagnosed 1995-2002. Eur J Cancer. 2009;45(6):992–1005.
3. Mitter V, Michel G, Strippoli M-PF, Rueegg CS, Rebholz CE, Feller M, Hau E,
Reck M, Niggli F, Hengartner H, et al. The Swiss childhood cancer registry.
Annual report 2009/2010. Bern: Institute of Social and Preventive Medicine,
University of Bern; 2011.
4. Alvarez JA, Scully RE, Miller TL, Armstrong FD, Constine LS, Friedman DL,
Lipshultz SE. Long-term effects of treatments for childhood cancers. Curr
Opin Pediatr. 2007;19(1):23–31.
5. Berkman AM, Lakoski SG. A Review of cardiorespiratory fitness in adolescent
and young adult survivors of childhood cancer: factors that affect its decline
and opportunities for intervention. J Adolesc Young Adult Oncol. 2016;5(1):
8–15.
6. Ness KK, Armstrong GT, Kundu M, Wilson CL, Tchkonia T, Kirkland JL. Frailty
in childhood cancer survivors. Cancer. 2015;121(10):1540–7.
7. Hudson MM, Ness KK, Gurney JG, et al. CLinical ascertainment of health
outcomes among adults treated for childhood cancer. JAMA. 2013;309(22):
2371–81.
8. Meadows AT. Pediatric cancer survivorship: research and clinical care. J Clin
Oncol. 2006;24(32):5160–5.
9. Leon AS, Connett J, Jacobs DRJ, Rauramaa R. Leisure-time physical activity
levels and the risk of coronary heart disease and death. The multiple risk
factor intervention trial. JAMA. 1987;258:2388–95.
10. Paffenbarger RS, Hyde RT, Wing AL, Lee I-M, Jung DL, Kampert JB. The
Association of Changes in physical-activity level and other lifestyle
characteristics with mortality among men. N Engl J Med. 1993;328(8):538–45.
11. Warburton D, Charlesworth S, Ivey A, Nettlefold L, Bredin S. A systematic
review of the evidence for Canada’s physical activity guidelines for adults.
Int J Behav Nutr Phys Act. 2010;7(1):39.
12. Reimers CD, Knapp G, Reimers AK. Exercise as stroke prophylaxis. Dtsch
Arztebl Int. 2009;106(44):715–21.
13. Kushi LH, Doyle C, McCullough M, Rock CL, Demark-Wahnefried W, Bandera
EV, Gapstur S, Patel AV, Andrews K, Gansler T, et al. American Cancer Society
guidelines on nutrition and physical activity for cancer prevention. CA
Cancer J Clin. 2012;62(1):30–67.
14. Deusinger SS. Exercise intervention for management of obesity. Pediatr
Blood Cancer. 2012;58(1):135–9.
15. Kelley GA, Kelley KS. Aerobic exercise and lipids and lipoproteins in men: a
meta-analysis of randomized controlled trials. J Mens Health Gend. 2006;
3(1):61–70.
16. Pedersen BK, Saltin B. Evidence for prescribing exercise as therapy in
chronic disease. Scand J Med Sci Sports. 2006;1:3–63.
17. Walker KZ, O'Dea K, Gomez M, Girgis S, Colagiuri R. Diet and exercise in the
prevention of diabetes. J Hum Nutr Diet. 2010;23(4):344–52.
18. Wolff I, van Croonenborg JJ, Kemper HCG, Kostense PJ, Twisk JW. The effect of
exercise training programs on bone mass: a meta-analysis of published controlled
trials in pre- and postmenopausal women. Osteoporos Int. 1999;9:1–12.
19. Gomez-Cabello A, Ara I, Gonzalez-Aguero A, Casajus JA, Vicente-Rodriguez
G. Effects of training on bone mass in older adults: a systematic review.
Sports Med. 2012;42(4):301–25.
20. Nikander R, Sievanen H, Heinonen A, Daly RM, Uusi-Rasi K, Kannus P.
Targeted exercise against osteoporosis: a systematic review and meta-
analysis for optimising bone strength throughout life. BMC Med. 2010;8:47.
21. Specker B, Thiex NW, Sudhagoni RG. Does exercise influence pediatric
bone? A systematic review. Clin Orthop Relat Res. 2015;473(11):3658–72.
22. Burton C, McKinstry B, Szentagotai Tatar A, Serrano-Blanco A, Pagliari C,
Wolters M. Activity monitoring in patients with depression: a systematic
review. J Affect Disord. 2012;4:4.
23. Rimer J, Dwan K, Lawlor DA, Greig CA, McMurdo M, Morley W, Mead GE.
Exercise for depression. Cochrane Database Syst Rev. 2012;11:7.
24. Jedrziewski MK, Lee VM, Trojanowski JQ. Physical activity and cognitive
health. Alzheimers Dement. 2007;3(2):98–108.
25. Larson EB, Wang L, Bowen JD, McCormick WC, Teri L, Crane P, Kukull W.
Exercise is associated with reduced risk for incident dementia among
persons 65 years of age and older. Ann Intern Med. 2006;144(2):73–81.
26. Blaauwbroek R, Bouma M, Tuinier W, Groenier K, de Greef M, Meyboom- de
Jong B, Kamps W, Postma A. The effect of exercise counselling with
feedback from a pedometer on fatigue in adult survivors of childhood
cancer: a pilot study. Support Care Cancer. 2009;17(8):1041–8.
27. Järvelä LS, Kemppainen J, Niinikoski H, Hannukainen JC, Lähteenmäki PM,
Kapanen J, Arola M, Heinonen OJ. Effects of a home-based exercise program
on metabolic risk factors and fitness in long-term survivors of childhood acute
lymphoblastic leukemia. Pediatr Blood Cancer. 2012;59(1):155–60.
28. Miller WR, Rollnick S. The effectiveness and ineffectiveness of complex
behavioral interventions: impact of treatment fidelity. Contemp Clin Trials.
2014;37(2):234–41.
29. Morgan F, Battersby A, Weightman AL, Searchfield L, Turley R, Morgan H,
Jagroo J, Ellis S. Adherence to exercise referral schemes by participants -
what do providers and commissioners need to know? A systematic review
of barriers and facilitators. BMC Public Health. 2016;16:227.
30. Chan A, Tetzlaff JM, Altman DG, et al. Spirit 2013 statement: defining
standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–7.
31. Klakk H, Andersen LB, Heidemann M, Moller NC, Wedderkopp N. Six physical
education lessons a week can reduce cardiovascular risk in school children
aged 6-13 years: a longitudinal study. Scand J Public Health. 2014;42(2):128–36.
32. Andersen LB, Lauersen JB, Brond JC, Anderssen SA, Sardinha LB, Steene-
Johannessen J, McMurray RG, Barros MV, Kriemler S, Moller NC, et al. A new
approach to define and diagnose cardiometabolic disorder in children. J
Diabetes Res. 2015;2015:539835.
33. Kelly AS, Steinberger J, Jacobs DR, Hong CP, Moran A, Sinaiko AR. Predicting
cardiovascular risk in young adulthood from the metabolic syndrome, its
component risk factors, and a cluster score in childhood. Int J Pediatr Obes.
2011;6(2–2):e283–9.
34. Kriemler S, Zahner L, Schindler C, Meyer U, Hartmann T, Hebestreit H,
Brunner-La Rocca HP, van Mechelen W, Puder JJ. Effect of school based
physical activity programme (KISS) on fitness and adiposity in primary
schoolchildren: cluster randomised controlled trial. BMJ. 2010;340:c785.
35. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA,
Fruchart JC, James WP, Loria CM, Smith SC Jr. Harmonizing the metabolic
syndrome: a joint interim statement of the international diabetes federation
task force on epidemiology and prevention; National Heart, Lung, and
Blood Institute; American Heart Association; world heart federation;
international atherosclerosis society; and International Association for the
Study of obesity. Circulation. 2009;120(16):1640–5.
36. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome.
Lancet. 2010;375(9710):181–3.
37. Eisenmann JC. On the use of a continuous metabolic syndrome score in
pediatric research. Cardiovasc Diabetol. 2008;7:17.
Rueegg et al. BMC Cancer  (2017) 17:822 Page 12 of 15
38. Eisenmann JC, Laurson KR, DuBose KD, Smith BK, Donnelly JE. Construct
validity of a continuous metabolic syndrome score in children. Diabetol
Metab Syndr. 2010;2:8.
39. Gurka MJ, Ice CL, Sun SS, Deboer MD. A confirmatory factor analysis of the
metabolic syndrome in adolescents: an examination of sex and racial/ethnic
differences. Cardiovasc Diabetol. 2012;11:128.
40. Michel G, von der Weid N, Zwahlen M, Redmond S, Strippoli MP, Kuehni C.
Incidence of childhood cancer in Switzerland: the Swiss childhood cancer
registry. Pediatr Blood Cancer. 2008;50(1):46–51.
41. Michel G, von der Weid NX, Zwahlen M, Adam M, Rebholz CE, Kuehni CE.
The Swiss childhood cancer registry: rationale, organisation and results for
the years 2001–2005. Swiss Med Wkly. 2007;137:502–9.
42. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International classification
of childhood cancer, third edition. Cancer. 2005;103(7):1457–67.
43. Pocock SJ, Simon R. Sequential treatment assignment with balancing for
prognostic factors in the controlled clinical trial. Biometrics. 1975;31(1):103–15.
44. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research
electronic data capture (REDCap)−a metadata-driven methodology and
workflow process for providing translational research informatics support. J
Biomed Inform. 2009;42(2):377–81.
45. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves JW, Hill MN, Jones DH,
Kurtz T, Sheps SG, Roccella EJ. Recommendations for blood pressure
measurement in humans: an AHA scientific statement from the Council on
High Blood Pressure Research Professional and Public Education
Subcommittee. J Clin Hypertens (Greenwich). 2005;7(2):102–9.
46. Seidell JC, Perusse L, Despres JP, Bouchard C. Waist and hip circumferences
have independent and opposite effects on cardiovascular disease risk
factors: the Quebec family study. Am J Clin Nutr. 2001;74(3):315–21.
47. ACSM’s Guidelines for Exercise Testing and Prescription. In. Edited by
Medicine ACoS, 6 edn. Philadelphia: Lippincott Williams & Wilkins; 2000.
48. Durnin JV, Rahaman MM: The assessment of the amount of fat in the
human body from measurements of skinfold thickness. 1967. Br J Nutr 2003,
89(1):147–155.
49. Durnin JV, Womersley J. Body fat assessed from total body density and its
estimation from skinfold thickness: measurements on 481 men and women
aged from 16 to 72 years. Br J Nutr. 1974;32(1):77–97.
50. Plank LD. Dual-energy X- Ray absorptiometry and body composition. Curr
Opin Clin Nutr Metab Care. 2005;8(3):305–9.
51. Seabolt LA, Welch EB, Silver HJ. Imaging methods for analyzing body
composition in human obesity and cardiometabolic disease. Ann N Y Acad
Sci. 2015;1353:41–59.
52. Tothill P, Avenell A, Love J, Reid DM. Comparisons between Hologic, lunar and
Norland dual-energy X-ray absorptiometers and other techniques used for
whole-body soft tissue measurements. Eur J Clin Nutr. 1994;48(11):781–94.
53. Frank-Wilson AW, Johnston JD, Olszynski WP, Kontulainen SA. Measurement
of muscle and fat in postmenopausal women: precision of previously
reported pQCT imaging methods. Bone. 2015;75:49–54.
54. Wong AK, Hummel K, Moore C, Beattie KA, Shaker S, Craven BC, Adachi JD,
Papaioannou A, Giangregorio L. Improving reliability of pQCT-derived
muscle area and density measures using a watershed algorithm for muscle
and fat segmentation. J Clin Densitom. 2015;18(1):93–101.
55. Swinford RR, Warden SJ. Factors affecting short-term precision of
musculoskeletal measures using peripheral quantitative computed
tomography (pQCT). Osteoporos Int. 2010;21(11):1863–70.
56. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC.
Homeostasis model assessment: insulin resistance and β-cell function from
fasting plasma glucose and insulin concentrations in man. Diabetologia.
1985;28(7):412–9.
57. Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of
insulin sensitivity. Am J Phys. 1979;236(6):E667–77.
58. Borai A, Livingstone C, Kaddam I, Ferns G. Selection of the appropriate method
for the assessment of insulin resistance. BMC Med Res Methodol. 2011;11:158.
59. Yeckel CW, Weiss R, Dziura J, Taksali SE, Dufour S, Burgert TS, Tamborlane WV,
Caprio S: Validation of insulin sensitivity indices from oral glucose tolerance
test parameters in obese children and adolescents 2004, 89(3):1096–1101.
60. Schousboe JT, Shepherd JA, Bilezikian JP, Baim S. Executive summary of the
2013 International Society for Clinical Densitometry Position Development
Conference on bone densitometry. J Clin Densitom. 2013;16(4):455–66.
61. Keel C, Kraenzlin ME, Kraenzlin CA, Muller B, Meier C. Impact of
bisphosphonate wash-out prior to teriparatide therapy in clinical practice. J
Bone Miner Metab. 2010;28(1):68–76.
62. Patsch JM, Burghardt AJ, Yap SP, Baum T, Schwartz AV, Joseph GB, Link TM.
Increased cortical porosity in type 2 diabetic postmenopausal women with
fragility fractures. J Bone Miner Res. 2013;28(2):313–24.
63. Leslie WD, Aubry-Rozier B, Lamy O, Hans D. Manitoba bone density P: TBS
(trabecular bone score) and diabetes-related fracture risk. J Clin Endocrinol
Metab. 2013;98(2):602–9.
64. Schousboe JT, Vokes T, Broy SB, Ferrar L, McKiernan F, Roux C, Binkley N.
Vertebral fracture assessment: the 2007 ISCD official positions. J Clin
Densitom. 2008;11(1):92–108.
65. Genant HK, CY W, van Kuijk C, Nevitt MC. Vertebral fracture assessment
using a semiquantitative technique. J Bone Miner Res. 1993;8(9):1137–48.
66. Daly RM, Ducher G, Hill B, Telford RM, Eser P, Naughton G, Seibel MJ, Telford
RD. Effects of a specialist-led, school physical education program on bone
mass, structure, and strength in primary school children: a 4-year cluster
randomized controlled trial. J Bone Miner Res. 2016;31(2):289–98.
67. Eser P, Hill B, Ducher G, Bass S. Skeletal benefits after long-term retirement
in former elite female gymnasts. J Bone Miner Res. 2009;24(12):1981–8.
68. Fonseca A, Gordon CL, Barr RD. Peripheral quantitative computed
tomography (pQCT) to assess bone health in children, adolescents, and
young adults: a review of normative data. J Pediatr Hematol Oncol. 2013;
35(8):581–9.
69. Rauch F, Schoenau E. Peripheral quantitative computed tomography of the
proximal radius in young subjects–new reference data and interpretation of
results. J Musculoskelet Neuronal Interact. 2008;8(3):217–26.
70. Augat P, Gordon C, Lang T, Iida H, Genant H. Accuracy of cortical and
trabecular bone measurements with peripheral quantitative computed
tomography (pQCT). Phys Med Biol. 1998;43(10):2873–83.
71. Winterhalder L, Eser P, Widmer J, Villiger PM, Aeberli D. Changes in
volumetric BMD of radius and tibia upon antidepressant drug
administration in young depressive patients. J Musculoskelet Neuronal
Interact. 2012;12(4):224–9.
72. Michelsen J, Wallaschofski H, Friedrich N, Spielhagen C, Rettig R, Ittermann T,
Nauck M, Hannemann A. Reference intervals for serum concentrations of three
bone turnover markers for men and women. Bone. 2013;57(2):399–404.
73. Cavalier E, Souberbielle JC, Gadisseur R, Dubois B, Krzesinski JM, Delanaye P. Inter-
method variability in bone alkaline phosphatase measurement: clinical impact on
the management of dialysis patients. Clin Biochem. 2014;47(13–14):1227–30.
74. Janssen MJ, Wielders JP, Bekker CC, Boesten LS, Buijs MM, Heijboer AC, van
der Horst FA, Loupatty FJ, van den Ouweland JM. Multicenter comparison
study of current methods to measure 25-hydroxyvitamin D in serum.
Steroids. 2012;77(13):1366–72.
75. Koivula MK, Turpeinen U, Laitinen P, Risteli J. Comparison of automated 25-
OH vitamin D immunoassays with liquid chromatography isotope dilution
tandem mass spectrometry. Clin Lab. 2012;58(11–12):1253–61.
76. Garnero P, Borel O, Delmas PD. Evaluation of a fully automated serum assay
for C-terminal cross- linking telopeptide of type I collagen in osteoporosis.
Clin Chem. 2001;47(4):694–702.
77. Schmidt-Gayk H, Spanuth E, Kotting J, Bartl R, Felsenberg D, Pfeilschifter J,
Raue F, Roth HJ. Performance evaluation of automated assays for beta-
CrossLaps, N-MID-osteocalcin and intact parathyroid hormone (BIOROSE
multicenter study). Clin Chem Lab Med. 2004;42(1):90–5.
78. Gundberg CM, Nieman SD, Abrams S, Rosen H. Vitamin K Status and bone
health: an analysis of methods for determination of undercarboxylated
osteocalcin. J Clin Endocrinol Metab. 1998;83(9):3258–66.
79. Yeap BB, Alfonso H, Chubb SA, Gauci R, Byrnes E, Beilby JP, Ebeling PR,
Handelsman DJ, Allan CA, Grossmann M, et al. Higher serum
undercarboxylated osteocalcin and other bone turnover markers are
associated with reduced diabetes risk and lower estradiol concentrations in
older men. J Clin Endocrinol Metab. 2015;100(1):63–71.
80. Beastall GH, Ferguson KM, O'Reilly DS, Seth J, Sheridan B. Assays for follicle
stimulating hormone and luteinising hormone: guidelines for the provision
of a clinical biochemistry service. Ann Clin Biochem. 1987;24(Pt 3):246–62.
81. Muller C, Wallaschofski H, Brabant G, Wahnschaffe U, Samietz S, Nauck M,
Friedrich N. The association between IGF-I/IGFBP-3 and subclinical end points:
epidemiology faces the limits. J Clin Endocrinol Metab. 2014;99(8):2804–12.
82. Morin P, Herrmann F, Ammann P, Uebelhart B, Rizzoli R. A rapid self-
administered food frequency questionnaire for the evaluation of dietary
protein intake. Clin Nutr. 2005;24(5):768–74.
83. Bolek-Berquist J, Elliott ME, Gangnon RE, Gemar D, Engelke J, Lawrence SJ,
Hansen KE. Use of a questionnaire to assess vitamin D status in young
adults. Public Health Nutr. 2009;12(2):236–43.
Rueegg et al. BMC Cancer  (2017) 17:822 Page 13 of 15
84. Godfrey S. Exercise tests in assessing children with lung or heart disease.
Thorax. 1970;25:258.
85. Paridon SM, Alpert BS, Boas SR, Cabrera ME, Caldarera LL, Daniels SR, Kimball
TR, Knilans TK, Nixon PA, Rhodes J, et al. Clinical stress testing in the pediatric
age group: a statement from the American Heart Association Council on
cardiovascular disease in the young, committee on atherosclerosis,
hypertension, and obesity in youth. Circulation. 2006;113(15):1905–20.
86. Weisman IM, Marciniuk D, Martinez FJ, Sciurba F, Sue D, Myers J. ATS/ACCP
Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med.
2003;167(2):211–77.
87. Balady GJ, Berra K, Golding L, Gordon N, Mahler D, Myers J, Sheldahl L:
American College of Sports Medicine's guidelines for exercise testing and
prescription, Sixth edn. Baltimore: Lippincott Williams & Wilkins; 2000.
88. Grant S, Aitchison T, Henderson E, Christie J, Zare S, McMurray J, Dargie H. A
comparison of the reproducibility and the sensitivity to change of visual
analogue scales, borg scales, and likert scales in normal subjects during
submaximal exercise*. Chest. 1999;116(5):1208–17.
89. Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehabil
Med. 1970;2(2):92–8.
90. Daanen HA, Lamberts RP, Kallen VL, Jin A, Van Meeteren NL. A systematic
review on heart-rate recovery to monitor changes in training status in
athletes. Int J Sports Physiol Perform. 2012;7(3):251–60.
91. Strassmann A, Steurer-Stey C, Dalla Lana K, Zoller M, Turk A, Suter P, Puhan
M. Population-based reference values for the 1-min sit-to-stand test. Int J
Public Health. 2013;58:949–53.
92. Puhan MA, Siebeling L, Zoller M, Muggensturm P, ter Riet G. Simple functional
performance tests and mortality in COPD. Eur Respir J. 2013;42(4):956–63.
93. Bohannon RW, Magasi SR, Bubela DJ, Wang Y-C, Gershon RC. Grip and knee
extension muscle strength reflect a common construct among adults.
Muscle Nerve. 2012;46(4):555–8.
94. Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower
body strength in community-residing older adults. Res Q Exerc Sport. 1999;
70(2):113–9.
95. Ozalevli S, Ozden A, Itil O, Akkoclu A. Comparison of the sit-to-stand test
with 6 min walk test in patients with chronic obstructive pulmonary
disease. Respir Med. 2007;101(2):286–93.
96. Bohannon RW, Bubela DJ, Magasi SR, Wang Y-C, Gershon RC. Sit-to-stand
test: performance and determinants across the age-span. Isokinet Exerc Sci.
2010;18(4):235–40.
97. Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, Sayer AA.
A review of the measurement of grip strength in clinical and
epidemiological studies: towards a standardised approach. Age Ageing.
2011;40(4):423–9.
98. Fess EE. Grip strength. 2nd ed. Chicago: American Society of Hand
Therapists; 1992.
99. Watanabe T, Owashi K, Kanauchi Y, Mura N, Takahara M, Ogino T. The short-
term reliability of grip strength measurement and the effects of posture and
grip span. J Hand Surg. 2005;30(3):603–9.
100. Steeves JA, Tyo BM, Connolly CP, Gregory DA, Stark NA, Bassett DR. Validity
and reliability of the Omron HJ-303 tri-axial accelerometer-based
pedometer. J Phys Act Health. 2011;8(7):1014–20.
101. Troiano RP, Berrigan D, Dodd KW, Masse LC, Tilert T, McDowell M. Physical
Activity in the United States Measured by Accelerometer. Med Sci Sports
Exerc. 2008;40(1):181–8.
102. Kozey SL, Lyden K, Howe CA, Staudenmayer JW, Freedson PS.
Accelerometer output and MET values of common physical activities. Med
Sci Sports Exerc. 2010;42(9):1776–84.
103. Rowlands AV, Stiles VH. Accelerometer counts and raw acceleration output
in relation to mechanical loading. J Biomech. 2012;45(3):448–54.
104. Metzger JS, Catellier DJ, Evenson KR, Treuth MS, Rosamond WD, Siega-Riz
AM. Patterns of objectively measured physical activity in the United States.
Med Sci Sports Exerc. 2008;40(4):630–8.
105. Vainionpaa A, Korpelainen R, Vihriala E, Rinta-Paavola A, Leppaluoto J, Jamsa
T. Intensity of exercise is associated with bone density change in
premenopausal women. Osteoporos Int. 2006;17(3):455–63.
106. Sallis JF, Haskell WL, Wood PD, Fortmann SP, Rogers T, Blair SN, Paffenbarger
RS Jr. Physical activity assessment methodology in the Five-City project. Am
J Epidemiol. 1985;121(1):91–106.
107. Ainsworth BE, Jacobs DR, Leon AS. Validity and reliability of self-reported
physical activity status: the lipid research clinics questionnaire. Med Sci
Sports Exerc. 1993;25:92–8.
108. Sallis JF, Buono MJ, Roby JJ, Micale FG, Nelson JA. Seven-day recall and
other physical activity self-reports in children and adolescents. Med Sci
Sports Exerc. 1993;25:99–108.
109. Ruf K, Fehn S, Bachmann M, Moeller A, Roth K, Kriemler S, Hebestreit H.
Validation of activity questionnaires in patients with cystic fibrosis by
Accelerometry and cycle Ergometry. BMC Med Res Methodol. 2012;12:43.
doi: 10.1186/1471-2288-12-43.
110. Markland D, Hardy L. The exercise motivations inventory: preliminary
development and validity of a measure of individuals' reasons for
participation in regular physical exercise. Personal Individ Differ. 1993;15(3):
289–96.
111. Markland D, Ingledew DK. The measurement of exercise motives: factorial
validity and invariance across gender of a revised exercise motivations
inventory. Br J Health Psychol. 1997;2(4):361–76.
112. Ainsworth BE, Jacobs DR Jr, Leon AS. Validity and reliability of self-reported
physical activity status: the lipid research clinics questionnaire. Med Sci
Sports Exerc. 1993;25(1):92–8.
113. Ellert U, Ballach B-M. The SF-36 in the Federal Health Survey-description of a
current normal sample. Gesundheitswesen. 1999;61 Spec No.:S184–90.
114. Ware J, Kosinski M, Dewey J. How to score version 2 of the SF-36 health
survey. Lincoln: QualyMetric Incorporated; 2000.
115. Reulen RC, Zeegers MP, Jenkinson C, Lancashire ER, Winter DL, Jenney ME,
Hawkins MM. The use of the SF-36 questionnaire in adult survivors of
childhood cancer: evaluation of data quality, score reliability, and scaling
assumptions. Health Qual Life Outcomes. 2006;4:77.
116. Reulen RC, Winter DL, Lancashire ER, Zeegers MP, Jenney ME, Walters SJ,
Jenkinson C, Hawkins MM. Health-status of adult survivors of childhood
cancer: a large-scale population-based study from the British childhood
cancer survivor study. Int J Cancer. 2007;121(3):633–40.
117. Hudson MM, Mertens AC, Yasui Y, Hobbie W, Chen H, Gurney JG, Yeazel M,
Recklitis CJ, Marina N, Robison LR, et al. Health status of adult long-term
survivors of childhood cancer: a report from the childhood cancer survivor
study. JAMA. 2003;290(12):1583–92.
118. Essig S, von der Weid NX, M-PF S, Rebholz CE, Michel G, Rueegg CS, Niggli
FK, Kuehni CE, for the Swiss pediatric oncology G. Health-related quality of
life in long-term survivors of relapsed childhood acute lymphoblastic
leukemia. PLoS One. 2012;7(5):e38015.
119. Rueegg CS, Gianinazzi ME, Rischewski J, Beck Popovic M, Von der Weid NX,
Michel G, Kuehni CE. Health-related quality of life in survivors of childhood
cancer: the role of chronic health problems. J Cancer Surviv. 2013;7(4):511–22.
120. Makowiec-Dabrowska T, Koszada-Wlodarczyk W. The CIS20R questionnaire
and its suitability for prolonged fatigue studies. Med Pr. 2006;57(4):335–45.
121. Vercoulen JH, Swanink CM, Fennis JF, Galama JM, van der Meer JW,
Bleijenberg G. Dimensional assessment of chronic fatigue syndrome. J
Psychosom Res. 1994;38(5):383–92.
122. Beurskens A, Bultmann U, Kant I, Vercoulen J, Bleijenberg G, Swaen G.
Fatigue among working people: validity of a questionnaire measure. Occup
Environ Med. 2000;57(5):353–7.
123. Bultmann U, de Vries M, Beurskens AJ, Bleijenberg G, Vercoulen JH, Kant I.
Measurement of prolonged fatigue in the working population:
determination of a cutoff point for the checklist individual strength. J
Occup Health Psychol. 2000;5(4):411–6.
124. Derogatis L: Brief symptom inventory (BSI), administraion, scoring, and
procedure manual (third ed.). In. Minneapolis: Minneapolis National
Computer Services; 1993.
125. Franke G. BSI, brief symptom inventory, von L.R. Derogatis - Deutsches
manual. Göttingen: Beltz Test Gesellschaft; 2000.
126. Schweizerische Gesundheitsbefragung. In: Statistik Bf, editor. Erste
Ergebnisse [Swiss health survey 2007, first results], vol. 2008. Neuchâtel:
Bundesamt für Statistik; 2007.
127. Germann U. Abschlussbericht zur Volkszählung 2000. Neuchâtel: Swiss
Federal Statistical Office (SFSO); 2005.
128. Bopp M, Spoerri A, Zwahlen M, Gutzwiller F, Paccaud F, Braun-Fahrlander C,
Rougemont A, Egger M. Cohort profile: the Swiss National Cohort–a
longitudinal study of 6.8 million people. Int J Epidemiol. 2009;38(2):379–84.
129. Tanner JM (ed.). Growth at adolescence, 2 edn. Oxford: Blackwell; 1962.
130. Ruf K, Winkler B, Hebestreit A, Gruber W, Hebestreit H. Risks associated with
exercise testing and sports participation in cystic fibrosis. J Cyst Fibros. 2010;
9(5):339–45.
131. CTCAE: The Common Terminology Criteria for Adverse Events (CTCAE). https://
ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm.
Rueegg et al. BMC Cancer  (2017) 17:822 Page 14 of 15
132. Armenian SH, Hudson MM, Mulder RL, Chen MH, Constine LS, Dwyer M,
Nathan PC, Tissing WJE, Shankar S, Sieswerda E, et al. Recommendations for
cardiomyopathy surveillance for survivors of childhood cancer: a report
from the international late effects of childhood cancer guideline
harmonization group. Lancet Oncol. 2015;16(3):e123–36.
133. Physical Activity Guidelines for Americans. In. Edited by Services UDoHaH.
Washington: Office of Disease Prevention and Health Promotion (ODPHP);
2008.
134. Engels JM, Diehr P. Imputation of missing longitudinal data: a comparison
of methods. J Clin Epidemiol. 2003;56(10):968–76.
135. Faude O, Kindermann W, Meyer T. Lactate threshold concepts: how valid
are they? Sports Med. 2009;39(6):469–90.
136. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows
AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, et al. Chronic
health conditions in adult survivors of childhood cancer. N Engl J Med.
2006;355(15):1572–82.
137. Boyle T, Keegel T, Bull F, Heyworth J, Fritschi L. Physical activity and risks of
proximal and distal colon cancers: a systematic review and meta-analysis. J
Natl Cancer Inst. 2012;
138. Cerhan JR, Chiu BC, Wallace RB, Lemke JH, Lynch CF, Torner JC, Rubenstein
LM. Physical activity, physical function, and the risk of breast cancer in a
prospective study among elderly women. J Gerontol A Biol Sci Med Sci.
1998;53(4):M251–6.
139. Samad AK, Taylor RS, Marshall T, Chapman MA. A meta-analysis of the
association of physical activity with reduced risk of colorectal cancer. Color
Dis. 2005;7(3):204–13.
140. Tardon A, Lee WJ, Delgado-Rodriguez M, Dosemeci M, Albanes D, Hoover R,
Blair A. Leisure-time physical activity and lung cancer: a meta-analysis.
Cancer Causes Control. 2005;16(4):389–97.
141. Mishra SI, Scherer RW, Geigle PM, Berlanstein DR, Topaloglu O, Gotay CC,
Snyder C. Exercise interventions on health-related quality of life for cancer
survivors. Cochrane Database Syst Rev. 2012;15:8.
142. Giovannucci EL. Physical activity as a standard cancer treatment. J Natl
Cancer Inst. 2012;104(11):797–9.
143. Brown JC, Huedo-Medina TB, Pescatello LS, Ryan SM, Pescatello SM, Moker
E, LaCroix JM, Ferrer RA, Johnson BT. The efficacy of exercise in reducing
depressive symptoms among cancer survivors: a meta-analysis. PLoS One.
2012;7(1):27.
144. McMillan EM, Newhouse IJ. Exercise is an effective treatment modality for
reducing cancer-related fatigue and improving physical capacity in cancer
patients and survivors: a meta-analysis. Appl Physiol Nutr Metab. 2011;36(6):
892–903.
145. Speck R, Courneya K, Mâsse L, Duval S, Schmitz K. An update of controlled
physical activity trials in cancer survivors: a systematic review and meta-
analysis. J Cancer Surviv. 2010;4:87–100.
146. Hamer M, Stamatakis E, Saxton J. The impact of physical activity on all-cause
mortality in men and women after a cancer diagnosis. Cancer Causes
Control. 2009;20(2):225–31.
147. Courneya KS. Physical activity in cancer survivors: a field in motion. Psycho-
Oncology. 2009;18(4):337–42.
148. Albrecht TA, Taylor AG. Physical activity in patients with advanced-stage
cancer: a systematic review of the literature. Clin J Oncol Nurs. 2012;16(3):
293–300.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Rueegg et al. BMC Cancer  (2017) 17:822 Page 15 of 15
